No Results

No Results


Oliguria is defined as a urine output that is less than 1 mL/kg/h in infants, less than 0.5 mL/kg/h in children, and less than 400 mL daily in adults. It is one of the clinical hallmarks of renal failure and has been used as a criterion for diagnosing and staging acute kidney injury (AKI), previously referred to as acute renal failure. At onset, oliguria is frequently acute. It is often the earliest sign of impaired renal function and poses a diagnostic and management challenge to the clinician. (See Presentation and Workup.) [1, 2]

A standardized definition of AKI has recently been proposed by the Kidney Disease: Improving Global Outcomes (KDIGO) AKI working group, which identifies and stages AKI based on changes in serum creatinine from baseline or a decrease in urine output (oliguria) as shown below. [3]

KDIGO Staging of AKI (Open Table in a new window)

Increase by 1.5-1.9 times baseline within 7 days


Increase by 3 times baseline or greater


Increase to 4 mg/dL (353.6 µmol/L) or greater


Renal replacement therapy initiation


Less than 0.3 mL/kg/h for 24 hours or longer



Not all cases of acute kidney injury are characterized by oliguria. Renal failure that results from nephrotoxic injury, interstitial nephritis, or neonatal asphyxia is frequently of the nonoliguric type, is related to a less severe renal injury, and has a better prognosis. In addition, the degree of oliguria depends on hydration and the concomitant use of diuretics.

In most clinical situations, acute oliguria is reversible and does not result in intrinsic renal failure. However, identification and timely treatment of reversible causes is crucial because the therapeutic window may be small. (See Prognosis, Presentation, Workup, Treatment, and Medication.)

For patient education information, see the Diabetes Center, as well as Acute Kidney Failure and Chronic Kidney Disease.

Oliguria may result from prerenal, intrinsic renal, or postrenal processes.

Prerenal insufficiency is a functional response of structurally normal kidneys to hypoperfusion. Globally, prerenal insufficiency accounts for approximately 70% of community-acquired cases of acute renal failure and as many as 60% of hospital-acquired cases. A decrease in circulatory volume evokes a systemic response aimed at normalizing intravascular volume at the expense of the glomerular filtration rate (GFR). Baroreceptor-mediated activation of the sympathetic nervous system and renin-angiotensin axis results in renal vasoconstriction and the resultant reduction in the GFR. The early phase also includes enhanced tubular reabsorption of salt and water (stimulated by the renin-angiotensin-aldosterone system and sympathetic nervous system), resulting in a decrease in fractional excretion of sodium (FENa) and decreased urine output. See the image below.

The early phase of renal compensation for reduced perfusion includes autoregulatory maintenance of the GFR via afferent arteriolar dilatation (induced by myogenic responses, tubuloglomerular feedback, and prostaglandins) and via efferent arteriolar constriction (mediated by angiotensin II). These changes are shown in the image below.

Iatrogenic interference with renal autoregulation by administration of vasoconstrictors (eg, cyclosporine, tacrolimus), inhibitors of prostaglandin synthesis (eg, nonsteroidal anti-inflammatory drugs), or angiotensin-converting enzyme (ACE) inhibitors can precipitate oliguric acute renal failure in individuals with reduced renal perfusion.

Rapid reversibility of oliguria following timely reestablishment of renal perfusion is an important characteristic and is the usual scenario in prerenal insufficiency. For example, oliguria in infants and children is most often secondary to dehydration and reverses without renal injury if the dehydration is corrected. However, prolonged renal hypoperfusion can result in a deleterious shift from compensation to decompensation.

This decompensation phase is characterized by excessive stimulation of the sympathetic and renin-angiotensin systems, with resultant profound renal vasoconstriction and ischemic renal injury.

Intrinsic renal failure is associated with structural renal damage. This includes acute tubular necrosis (from prolonged ischemia, drugs, or toxins), primary glomerular diseases, or vascular lesions. Recent experimental studies indicate that prerenal and intrinsic renal failure are distinct molecular entities and hence different disease states, despite similar degrees of oliguria and similar increases in serum creatinine concentrations. Prerenal failure is characterized by induction of protective molecular mechanisms within the kidney, whereas intrinsic renal failure upregulates kidney genes and pathways of cell injury, cell death, and inflammation. [4]

Advancements in the care of critically ill neonates, infants with congenital heart disease, and children who undergo bone marrow and solid organ transplantation have led to a dramatic broadening of the etiology of pediatric acute kidney injury. Although multicenter etiologic data on pediatric acute renal failure are not available, single-center data and literature reviews from the 1980s and 1990s reported hemolytic uremic syndrome and other primary renal diseases as the most prevalent causes. [5, 6]

Subsequent single-center data have detailed the underlying causes of pediatric acute renal failure in large cohorts of children. In a study of 226 children with acute renal failure, Bunchman et al reported that congenital heart disease, acute tubular necrosis, sepsis, and bone marrow transplantation were the most common causes. [7]

A retrospective review of 248 patients with a diagnosis of acute renal failure upon discharge or death revealed acute tubular necrosis and nephrotoxins to be the most common causes of acute kidney injury. [8] Thus, the etiology of pediatric acute renal failure has evolved in industrialized countries from primary kidney diseases or prerenal failure to secondary effects of other systemic illnesses or their treatment.

The pathophysiology of ischemic acute tubular necrosis is well studied. Ischemia leads to altered tubule cell metabolism (eg, depletion of adenosine triphosphate [ATP], release of reactive oxygen species) and cell death, with resultant cell desquamation, cast formation, intratubular obstruction, backleak of tubular fluid, and oliguria. (See the image below.)

In most clinical situations, the oliguria is reversible and associated with repair and regeneration of tubular epithelial cells.

Postrenal failure is a consequence of the mechanical or functional obstruction of the flow of urine. This form of oliguria and renal insufficiency usually responds to the release of the obstruction.

Principal causes of oliguric acute kidney injury in neonates

The etiology of oliguria varies with age, and the common causes in neonates and children are listed separately. Patients with acute kidney injury secondary to nephrotoxins, interstitial nephritis, and perinatal asphyxia frequently do not have oliguria.

Prerenal causes include the following:

Perinatal asphyxia

Respiratory distress syndrome

Hemorrhage – Eg, maternal antepartum, twin-twin transfusion, and intraventricular



Sepsis or shock

Congenital heart disease


Drugs – Eg, indomethacin, maternal nonsteroidal anti-inflammatory drugs (NSAIDs), and maternal ACE inhibitors

Intrinsic renal causes include the following:

Acute tubular necrosis

Exogenous toxins – Eg, aminoglycosides, amphotericin B, and contrast agents

Endogenous toxins – Eg, hemoglobin, myoglobin, and uric acid

Congenital kidney disease – Eg, agenesis, polycystic kidney, hypoplasia, and dysplasia

Vascular – Eg, renal vein thrombosis and renal artery thrombosis

Transient renal dysfunction of the newborn

Postrenal causes include the following:

Bladder outlet obstruction – Eg, posterior urethral valves and meatal stenosis

Neurogenic bladder

Ureteral obstruction, bilateral

Prerenal causes include the following:

Gastrointestinal (GI) losses – Eg, vomiting and diarrhea

Blood losses – Eg, hemorrhage

Renal losses – Eg, diabetes insipidus, diabetes mellitus, diuretics, and salt-wasting nephropathy

Cutaneous losses – Eg, burns

Third space losses – Eg, surgery, trauma, nephrotic syndrome, and capillary leak

Shock – Eg, septic, toxic, and anaphylactic

Impaired autoregulation – Eg, cyclosporine, tacrolimus, ACE inhibitors, and NSAIDs

Impaired cardiac output – Eg, congenital and acquired heart disease

Intrinsic renal causes include the following:

Acute tubular necrosis – Eg, prolonged prerenal failure


Interstitial nephritis, vascular – Eg, hemolytic-uremic syndrome and vasculitis

Exogenous toxins – Eg, aminoglycosides, amphotericin B, cyclosporine, chemotherapy, heavy metals, and contrast agents

Endogenous toxins – Eg, hemoglobin, myoglobin, and uric acid

Transplant rejection

Postrenal causes include the following:

Bladder outlet obstruction – Eg, posterior urethral valves, blocked catheter, and urethral trauma

Neurogenic bladder

Ureteral obstruction, bilateral

The frequency of oliguria widely varies depending on the clinical setting. In adults, the incidence is about 1% at admission, 2-5% during hospitalization, and 4-15% after cardiopulmonary bypass.

Oliguric acute kidney injury occurs in approximately 10% of newborn intensive care unit (ICU) patients. The incidence in children undergoing cardiac surgery is as high as 10-30%. Among critically ill children admitted to pediatric ICUs (PICUs), the incidence of acute kidney injury defined by doubling of serum creatinine is present in about 5-6%. This was illustrated by a prospective study from a Canadian PICU that identified 985 cases of acute kidney injury for an incidence rate of 4.5% of all PICU admissions. [9] In the largest study reported to date, 3396 admissions to a single PICU in the United States were retrospectively analyzed. [10] Using serum creatinine criteria, 6% of children had acute kidney injury on admission and 10% developed acute kidney injury during their PICU stay.

A recent landmark international study of 4683 critically ill children utilized the KDIGO definition of AKI to demonstrate that the incidence of AKI was 27% when both serum creatinine and urine output criteria were used. Notably, more than two-thirds of the patients with oliguria did not meet the serum creatinine criteria for AKI – and low urine output alone conferred a significantly increased risk of death compared to elevated serum creatinine alone. [11]

Oliguria affects people of all ages. It is more common in neonatal and older age groups because of comorbid conditions and is more common in early childhood because of the high incidence of illnesses that lead to dehydration.

Mortality rates in oliguric acute kidney injury widely vary according to the underlying cause and associated medical condition. It ranges from 5% for patients with community-acquired kidney injury failure to 80% among patients with multiorgan failure in the ICU.

In general, severe acute kidney injury can have serious short- and long-term consequences. The outcome depends upon the etiology, age of the child, and comorbidities. In terms of mortality, severe acute kidney injury requiring renal replacement therapy in children is still associated with a mortality rate of about 30-50%, and this has not changed appreciably over the past 3 decades. Infants younger than 1 year have the highest mortality rate.

In a PICU cohort, patients who presented with acute kidney injury on admission had a 32% mortality rate, and those who developed acute kidney injury at any time during the PICU stay had a 30% mortality rate. [10] Additionally, those with any degree of acute kidney injury at the time of PICU admission had higher PICU mortality than those with normal kidney function. Moreover, patients who developed any degree of acute kidney injury during PICU stay had higher ICU mortality than those without acute kidney injury during PICU stay. Multivariate logistic regression modeling controlling for age, sex, weight, race, and pediatric index of mortality score confirmed that acute kidney injury on admission to the PICU was associated with an increased risk of mortality (adjusted odds ratio, 5.4; 95% CI, 3.5-8.4). Development of acute kidney injury during the PICU stay was associated with an even greater risk of mortality (adjusted odds ratio, 8.7; 95% CI, 6.0-12.6) and a 4-fold increase in length of hospital stay.

In a retrospective analysis of 344 patients from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry, the overall mortality rate was 42%. [12] Survival was lowest in liver disease/transplantation (31%), pulmonary disease/transplantation (45%), and bone marrow transplantation (45%). Overall survival was better for children who weighed more than 10 kg (63% vs 43%; P = .001) and for those who were older than 1 year (62% vs 44%; P = .007).

Thus, it is now clear that patients die of acute kidney injury and its complications, and not simply with acute kidney injury. [13] The patient succumbs largely because of involvement of multiple other systems during the period of severe oliguric renal insufficiency. The most common causes of death are sepsis and cardiovascular or pulmonary dysfunction.

Information regarding the long-term outcome of children after an episode of severe acute kidney injury is scant but is beginning to accumulate. [14]

In a multicenter pooled analysis of 3476 children with hemolytic uremic syndrome followed for a mean of 4.4 years, [15] the combined average death and end-stage renal disease (ESRD) rate was 12% (95% CI, 10-15%) and the combined average renal sequelae rate (chronic kidney disease, proteinuria, hypertension) was 25% (95% CI, 20-30%). Thus, long-term follow-up appears to be warranted after an acute episode of hemolytic uremic syndrome.

In a retrospective study of 176 children who developed acute kidney injury in a single center, 34% had either reduced kidney function or were dialysis dependent at hospital discharge. [8] Upon 3-5 years of follow up of the same cohort, the mortality rate was 20%. [16] Approximately 60% developed evidence for chronic kidney disease (proteinuria, decreased glomerular filtration rate, hypertension) and 9% developed ESRD.

Collectively, these data strongly suggest that long-term follow-up is warranted for children who survive an episode of acute kidney injury.

In contrast to the above, the prognosis from prerenal causes of acute kidney injury or from acute tubular necrosis in the absence of significant comorbid conditions is usually quite good if appropriate therapy is instituted in a timely fashion.

Infections develop in 30-70% of patients and affect the respiratory system, urinary tract, and indwelling catheters. Impaired defenses due to uremia and the inappropriate use of broad-spectrum antibiotics may contribute to the high rate of infectious complications.

Cardiovascular complications are a result of fluid and sodium retention. They include hypertension, congestive heart failure, and pulmonary edema. Hyperkalemia results in electrocardiographic abnormalities and arrhythmias.

Other complications include the following:

GI – Anorexia, nausea, vomiting, ileus, and bleeding

Hematologic – Anemia and platelet dysfunction

Neurologic – Confusion, asterixis, somnolence, and seizures

Other electrolyte/acid-base disorders – Metabolic acidosis, hyponatremia, hypocalcemia, and hyperphosphatemia

Cerda J. Oliguria: an earlier and accurate biomarker of acute kidney injury?. Kidney Int. 2011 Oct. 80(7):699-701. [Medline].

Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004 Aug. 8(4):R204-12. [Medline]. [Full Text].

KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012. 2:1:

Devarajan P. Acute kidney injury: Acute kidney injury: still misunderstood and misdiagnosed. Nat Rev Nephrol. 2017 Feb 6. [Medline].

Mehrazma M, Hooman N, Otukesh H. Prognostic value of renal pathological findings in children with atypical hemolytic uremic syndrome. Iran J Kidney Dis. 2011 Nov. 5(6):380-5. [Medline].

Adragna M, Balestracci A, García Chervo L, Steinbrun S, Delgado N, Briones L. Acute dialysis-associated peritonitis in children with D+ hemolytic uremic syndrome. Pediatr Nephrol. 2011 Oct 29. [Medline].

Bunchman TE, McBryde KD, Mottes TE, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol. 2001 Dec. 16(12):1067-71. [Medline].

Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis. 2005 Jan. 45(1):96-101. [Medline].

Bailey D, Phan V, Litalien C, et al. Risk factors of acute renal failure in critically ill children: A prospective descriptive epidemiological study. Pediatr Crit Care Med. 2007 Jan. 8(1):29-35. [Medline].

Schneider J, Khemani R, Grushkin C, Bart R. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Crit Care Med. 2010 Mar. 38(3):933-9. [Medline].

Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL, AWARE Investigators. Epidemiology of Acute Kidney Injury in Critically Ill Children and Young Adults. N Engl J Med. 2017 Jan 5. 376 (1):11-20. [Medline].

Symons JM, Chua AN, Somers MJ, et al. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol. 2007 Jul. 2(4):732-8. [Medline].

Goldstein SL, Devarajan P. Pediatrics: Acute kidney injury leads to pediatric patient mortality. Nat Rev Nephrol. 2010 Jul. 6(7):393-4. [Medline].

Goldstein SL, Devarajan P. Acute kidney injury in childhood: should we be worried about progression to CKD?. Pediatr Nephrol. 2011 Apr. 26(4):509-22. [Medline].

Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003 Sep 10. 290(10):1360-70. [Medline].

Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL. 3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int. 2006 Jan. 69(1):184-9. [Medline].

Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011 Nov 22. 58(22):2301-9. [Medline]. [Full Text].

Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol. 2011 May. 22(5):810-20. [Medline].

Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004 Sep. 44(3):402-9. [Medline].

Gambaro G, Bertaglia G, Puma G, D’Angelo A. Diuretics and dopamine for the prevention and treatment of acute renal failure: a critical reappraisal. J Nephrol. 2002 May-Jun. 15(3):213-9. [Medline].

Onder AM, Rosen D, Mullett C, Cottrell L, Kanosky S, Grossman OK, et al. Comparison of Intraoperative Aminophylline Versus Furosemide in Treatment of Oliguria During Pediatric Cardiac Surgery. Pediatr Crit Care Med. 2016 Aug. 17 (8):753-63. [Medline].

Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007 Aug 23. 357(8):797-805. [Medline].

American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol. 2005 Jul. 16(7):1886-903. [Medline]. [Full Text].

Andreoli SP. Acute kidney injury in children. Pediatr Nephrol. 2009 Feb. 24(2):253-63. [Medline]. [Full Text].

Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012 May 18. [Medline].

Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011 Nov. 121(11):4210-21. [Medline]. [Full Text].

Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov. 16(11):3365-70. [Medline].

Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr. 2005 Apr. 17(2):193-9. [Medline].

Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006 Jun. 17(6):1503-20. [Medline].

Devarajan P, Goldstein SL. Acute renal failure. Kher KK, Schnaper HW, Makker SP. Clinical Pediatric Nephrology. Second Edition. Oxon, UK: Informa Healthcare; 2007. 3770390.

Goldstein SL. Pediatric acute kidney injury: it’s time for real progress. Pediatr Nephrol. 2006 Jul. 21(7):891-5. [Medline].

Goldstein SL. Pediatric acute renal failure: demographics and treatment. Contrib Nephrol. 2004. 144:284-90. [Medline].

Gouyon JB, Guignard JP. Management of acute renal failure in newborns. Pediatr Nephrol. 2000 Sep. 14(10-11):1037-44. [Medline].

Klahr S, Miller SB. Acute oliguria. N Engl J Med. 1998 Mar 5. 338(10):671-5. [Medline].

Lameire NH, De Vriese AS, Vanholder R. Prevention and nondialytic treatment of acute renal failure. Curr Opin Crit Care. 2003 Dec. 9(6):481-90. [Medline].

Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change?. J Am Soc Nephrol. 2003 Aug. 14(8):2178-87. [Medline]. [Full Text].

Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004 Oct. 66(4):1613-21. [Medline].

Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. 2004 Aug. 66(2):496-9. [Medline].

Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004 Nov 13-19. 364(9447):1814-27. [Medline].

Rabb H, Colvin RB. Case records of the Massachusetts General Hospital. Case 31-2007. A 41-year-old man with abdominal pain and elevated serum creatinine. N Engl J Med. 2007 Oct 11. 357(15):1531-41. [Medline].

Racusen LC. The morphologic basis of acute renal failure. Molitoris BA, Finn WF, eds. Acute Renal Failure. Philadelphia, PA: WB Saunders; 2004. 1-12.

Safirstein RL. Acute renal failure: from renal physiology to the renal transcriptome. Kidney Int Suppl. 2004 Oct. S62-6. [Medline].

Schrier RW. Need to intervene in established acute renal failure. J Am Soc Nephrol. 2004 Oct. 15(10):2756-8. [Medline]. [Full Text].

Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004 Jul 8. 351(2):159-69. [Medline].

Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004 Jul. 114(1):5-14. [Medline]. [Full Text].

Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol. 2011 Apr. 7(4):189-200. [Medline].

Siegel NJ, Van Why SK, Devarajan P. Pathogenesis of acute renal failure. Avner ED, Harmon WE, Niaudet P, eds. Pediatric Nephrology. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. 1223.

Star RA. Treatment of acute renal failure. Kidney Int. 1998 Dec. 54(6):1817-31. [Medline].

Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005 Aug 17. 294(7):813-8. [Medline].

Warnock DG. Towards a definition and classification of acute kidney injury. J Am Soc Nephrol. 2005 Nov. 16(11):3149-50. [Medline].

Increase by 1.5-1.9 times baseline within 7 days


Increase by 3 times baseline or greater


Increase to 4 mg/dL (353.6 µmol/L) or greater


Renal replacement therapy initiation


Less than 0.3 mL/kg/h for 24 hours or longer


Prasad Devarajan, MD, FAAP Louise M Williams Endowed Chair in Pediatrics, Professor of Pediatrics and Developmental Biology, Director of Nephrology and Hypertension, Director of the Nephrology Fellowship Program, Medical Director of the Kidney Stone Center, Co-Director of the Institutional Office of Pediatric Clinical Fellowships, Director of Clinical Nephrology Laboratory, CEO of Dialysis Unit, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine

Prasad Devarajan, MD, FAAP is a member of the following medical societies: American Heart Association, American Society of Nephrology, American Society of Pediatric Nephrology, National Kidney Foundation, Society for Pediatric Research

Disclosure: Received none from Coinventor on patents submitted for the use of NGAL as a biomarker of kidney injury for none.

Craig B Langman, MD The Isaac A Abt, MD, Professor of Kidney Diseases, Northwestern University, The Feinberg School of Medicine; Division Head of Kidney Diseases, The Ann and Robert H Lurie Children’s Hospital of Chicago

Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, International Society of Nephrology

Disclosure: Received income in an amount equal to or greater than $250 from: Alexion Pharmaceuticals; Horizon Pharmaceuticals); ; Dicerna, Jannsen Pharmaceuticals.

Laurence Finberg, MD Clinical Professor, Department of Pediatrics, University of California, San Francisco, School of Medicine and Stanford University School of Medicine

Laurence Finberg, MD is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.

Luther Travis, MD Professor Emeritus, Departments of Pediatrics, Nephrology and Diabetes, University of Texas Medical Branch School of Medicine

Luther Travis, MD is a member of the following medical societies: Alpha Omega Alpha, American Federation for Medical Research, International Society of Nephrology, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.


Research & References of Oliguria|A&C Accounting And Tax Services

12 thoughts on “Oliguria

  1. Pingback: viagra buy
  2. Pingback: viagra pill
  3. Pingback: rxtrust pharm
  4. Pingback: rxtrustpharm.com
  5. Pingback: rxtrustpharm
  6. Pingback: buy levitra in uk

Leave a Reply